Clinical trials
Observational Depressive Disorder trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 7 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 30 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 2 |
| Max-Planck-Institute of Psychiatry | 2 |
| Shanghai Mental Health Center | 2 |
| University Hospital, Bonn | 2 |
| University Hospital, Strasbourg, France | 2 |
| Air Force Military Medical University, China | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Brown University | 1 |
| Centre Médical Porte Verte | 1 |
| Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Depressive Disorder | 30 |
| Anxiety Disorders | 11 |
| Bipolar Disorder | 6 |
| Mental Disorders | 3 |
| Stress Disorders, Post-Traumatic | 3 |
| Major Depressive Disorder | 2 |
| Mood Disorders | 2 |
| Personality Disorders | 2 |
| Substance-Related Disorders | 2 |
| Acute Coronary Syndrome | 1 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.